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ABSTRACT: Screening of an in-house library of compounds identified 12-thiazole abietanes as a new class of reversible inhibitors 
of the human metabolic serine hydrolase. Further optimization of the first hit compound lead to the 2-methylthiazole derivative 18, 
with an IC50 value of 3.4 ± 0.2 µM and promising selectivity. ABHD16A has been highlighted as a new target for inflammation-
mediated pain, although selective inhibitors of hABHD16A (human ABHD16A) have not yet been reported. Our study presents 
abietane-type diterpenoids as an attractive starting point for the design of selective ABHD16A inhibitors, which will contribute 
towards understanding the significance of hABHD16A inhibition in vivo.
Inflammation of tissue within the peripheral and central nervous 
system, known as neuroinflammation, has been implicated in 
the development of chronic pain via sensitization of nociceptive 
neurons.1,2 Therefore, identifying and targeting the processes 
and molecules involved in neuroinflammation is regarded as an 
effective strategy for innovative chronic pain treatments. In this 
regard, the metabolic serine hydrolase ABHD16A, also known 
as BAT5, belonging to the ABHD (α,β-hydrolase domain) 
enzyme family is a potentially novel key target in inflammation-
mediated pain.3,4 This enzyme is mostly expressed in the brain, 
muscle, heart and testis, where its activity is closely coupled 
with that of ABHD12 to regulate the levels of pro-inflammatory 
lysophosphatidylserine (lyso-PS).3,5 More specifically, 
ABHD16A converts phosphatidylserine (PS) to lyso-PS, which 
is either recycled back to PS or further hydrolyzed by ABHD12 
to glycerophosphoserine. Accordingly, deletion of ABHD12 
results in high levels of lyso-PS in the brain and microglial 
activation whereas pharmacological or genetic perturbation of 
ABHD16A decreases the levels of lyso-PS and ameliorates 
inflammation. It is therefore desirable to block the activity of 
ABHD16A without concomitant inhibition of ABHD12.
ABHD16A is a membrane-bound enzyme and in the absence of 
a crystal structure, the search for inhibitors has been based on 
competitive activity-based protein profiling (ABPP).3,6 
Palmostatin B, tetrahydrolipstatin (THL), 1,3,4-oxadiazol-
2(3H)-ones and KC01 have all been reported to inhibit 
ABHD16A, some with nanomolar potency, however the 
selectivity is still poor (Figure 1).3,6,7
Previously, we have shown that pentacyclic triterpenoids 
including maslinic acid bear unprecedented selectivity for 
inhibition of ABHD12 over other serine hydrolases, as well as 
over cannabinoid receptors.8 A ligand-based pharmacophore 
model highlighted the planar hydrophobic hydrocarbon core 
among the relevant pharmacophoric features. Compounds in 
this class of triterpenoids, however, have high molecular 
weights and poor aqueous solubility, which limits their use in 
biological assays and further development into drug leads. 
Smaller molecular weight diterpenoids of the abietane family 
are much more interesting from this perspective especially 
because a few, including methyl carnosate and miltirone, cross 
the blood-brain barrier and bear analgesic properties.9
MeO
MeO
O
O
O
O
O
O
HN
O
()-Tetrahydrolipstatin6
IC50 = 170 nM
Other activities: ABHD6, ABHD127
Palmostatin B6
IC50 = 100 nM
RPa = 1.7
Other activities: ABHD12, LYPLA1/26
O
O
NH2
O
11
8
KC013
IC50 = 90 ± 20 nM
RPa = 1.3
Other activities: ABHD2, ABHD33
N
O
N
OMeO
F
Compound 446
IC50 = 32 nM
RPa = 5.3
Other activities: KIAA13636
6
Figure 1. Examples of known ABHD16A inhibitors and their 
reported selectivity. aRP = Relative potency ratio related to THL 
expressed as IC50 (THL) / IC50 (compound), under the same assay 
conditions.
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Scheme 1. Synthesis of 12-thiazole abietanes 5–8 and 11–14 from dehydroabietic acid 1.
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Reagents and conditions: (a) MeI, K2CO3, DMF, rt, 2.5 h. (b) MeCOCl, AlCl3, CH2Cl2, 0 ºC  r.t., 3.5 h. (c) CuBr2, MeOH, 65 ºC, 16 h. 
(d) Thiourea, Et3N, dry EtOH, reflux, 1 h 45 min, or 120 ºC with microwaves, 30 min. (e) Thioformamide, dry 1,4-dioxane, 100 ºC with 
microwaves, 10 min. (f) LiAlH4, THF, 0 ºC  r.t. (g) KOH, ethylene glycol, H2O, 130 ºC. (h) HOBt, EDC-HCl, aq. NH3, DMF, 0 ºC  r.t., 
19 h.
 
When we screened an in-house library of 50 abietanes for their 
ability to inhibit hydrolase activity in lysates of HEK293 cells 
transiently overexpressing human ABHD16A,6 at 10 µM, 
ruling out concomitant inhibition of human ABHD12,7 the 2-
aminothiazole 5 (Scheme 1) was the only compound showing 
moderate inhibition of hABHD16A without interfering with 
hABHD12 (Table 1). Its synthesis proceeded from methyl 
dehydroabietate 2 which gave 3 by Fridel-Crafts acylation 
(Scheme 1),10 followed by bromination of the carbon alpha to 
the carbonyl group with CuBr2, in refluxing MeOH.11 The 
reaction resulted in a mixture of mono- and dibromo 
compounds 4a and 4b, which was used without further 
purification in the reaction with thiourea to give 5, in 40% yield, 
over two steps.
In the light of the well-known canonical esterase mechanism for 
/-hydrolase fold enzymes,12 we reasoned that the ring A ester 
in 5 would likely account for the observed activity. In addition, 
aminothiazoles are generally known to be promiscuous assay-
interfering compounds13 so it was important to determine 
whether the 2-amino substituent was relevant for the observed 
activity. The ester was first modified by reduction14 to alcohol 
7 or replaced with the amide 11, as depicted on Scheme 1. A 
thiazole derivative 6, devoid of a 2-amino substituent, was 
prepared by reacting 4 and thioformamide under microwave 
conditions, in 53% yield.
Modification of the ring A ester resulted in modest inhibition of 
hABHD16A in 7 and 11, whereas 6 inhibited the enzyme 
slightly more efficiently than 5. A new round of modifications 
of the ring A ester in 6 gave the amide 12 via a synthetic route 
similar to that of 11, and the carboxylic acid 13, from the 
alkaline hydrolysis of 6 (Scheme 1). Enzyme inhibition was 
almost abrogated with the amide 12 and the carboxylic acid 13. 
However, it was retained by the alcohol 8, even if less 
pronounced when compared to the ester 6 (Table 1). 
Table 1. Remaining hydrolase activity for hABHD12 and 
hABHD16A (% control) at 10 µM concentration.
Compound hABHD16A 
(% control)
Mean ± SD, n=2-3
hABHD12
(% control)
Mean ± SD, n=2-3
5 58.2 ± 18.1 102.6 ± 2.3
6 50.3 ± 4.6 91.5 ± 0.4
7 74.6 ± 7.5 87.8 ± 0.8
8 65.9 ± 2.8 96.3 ± 1.0
11 80.0 ± 5.6 96.9 ± 0.8
12 82.1 ± 4.3 98.7 ± 0.2
13 91.5 ± 2.8 98.4 ± 0.2
14 62.9 ± 3.4 77.8 ± 1.0
15 73.8 ± 4.7 89.8 ± 0.1
16 86.6 ± 0.8 100.9 ± 4.1
17 99.3 ± 2.4 96.6 ± 8.8
18 23.0 ± 16.3 100.1 ± 1.1
19 48.7 ± 0.5 73.8 ± 3.2
20 42.8 ± 4.1 94.3 ± 0.7
21 66.3 ± 5.9 98.7 ± 2.2
22 98.4 ± 0.8 101.9 ± 0.0
23 80.6 ± 1.8 99.6 ± 1.0
24 82.7 ± 4.2 92.8 ± 1.2
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25 81.5 ± 4.9 91.1 ± 1.7
26 80.1 ± 1.6 91.1 ± 2.9
Interestingly, 14, which was the main product obtained in the 
hydrolysis reaction of 6, showed inhibition of hABHD16A 
comparable to that of the alcohol 8, however with weaker 
selectivity, as approximately 20% inhibition of ABHD12 was 
observed. Overall these results suggested that both the thiazole 
ring and the substituent at ring A were relevant for the activity 
with the 2-amino substituent in the heterocycle not being an 
essential feature, and ring A substitution being flexible between 
an ester and an alcohol, the ester performing better in terms of 
potency and selectivity.
We proceeded to study what substituents were tolerated at 
position 2 of the thiazole ring. We synthesized the bulky phenyl 
and chlorophenyl derivatives 15–17 with the methyl ester at 
C18, according to Scheme 2. The chlorophenyl compounds 16 
and 17 did not inhibit hABHD16A, and 15 was a modest 
inhibitor.
Scheme 2. Variation of the position 2 of the thiazole ring.
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Reagents and conditions: (a) Respective thioamide, dry EtOH, 
120 ºC with microwaves. (b) 7 M NH3 in MeOH, r.t., 2 d. (c) Et3N, 
TFAA, THF, 0 ºC  r.t, 3 h. (d) LiAlH4, THF, 0 ºC  r.t., 2 h. (e) 
KOH, ethylene glycol, H2O, 130 ºC, 1 d. (f) HOBt, EDC-HCl, aq. 
NH3, DMF, 0 ºC  r.t., 22 h.
Introduction of the less bulky methyl group at position 2 of the 
thiazole ring resulted in 18, the most active compound in the set 
with approximately 80% inhibition of the activity of 
hABHD16A, and no inhibition of hABHD12 (Scheme 2). We 
again ruled out the effect of having the methyl ester on ring A 
by synthesizing the carboxylic acid and amide derivatives 22 
and 23, respectively. Compound 23 was synthesized following 
activation of 22 with hydroxybenzotriazole (HOBt) and N-(3-
dimethylaminopropyl)-N′-ethylcarbodiimide hydrochloride 
(EDC-HCl), and further reaction with ammonia, in 77% yield. 
As before, inhibition of hABH16A was almost abrogated in the 
carboxylic acid and amide derivatives whereas the alcohol 21 
was half as potent as the parent ester (Table 1). The synthesis 
of 20, where the methyl substituent was replaced by an electron-
withdrawing nitrile group, proceeded from 4 and ethyl 
thiooxamate and continued with the hydrolysis of 19, with NH3 
in MeOH to give an intermediate amide, which was further 
converted to the nitrile 20 using trifluoroacetic acid and 
triethylamine in tetrahydrofuran, in 46% yield.15 Both 19 and 
20 inhibited the activity of hABDH16A by approximately 60%, 
with 20 being selective. Altogether, we concluded that the 
bulkiness of the substituent at position 2 of the thiazole ring 
seems to be more relevant for the activity than its electron 
donating or withdrawing ability.
The synthesis of the thiazolium salts 24–26, where the ring 
nitrogen is no longer available for hydrogen bonding and is in 
addition more prone to nucleophilic attack, was attempted next 
(Scheme 3). Compound 18 and iodomethane or iodoethane, 
respectively, were refluxed in acetone to give 24 and 25, in 73% 
and 11% yield respectively.16 Compound 26 was obtained 
similarly from 6 and iodomethane in 65% yield. None of the 
thiazolium derivatives inhibited the activity of hABHD16A 
significantly, which confirms that the thiazole ring is most 
likely implicated in positioning of the compound in the enzyme 
active site.
Scheme 3. Synthesis of the thiazolium salts 24−26
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We characterized in more detail the two most promising 
hABHD16A inhibitors of the series, 18 and 20. The dose-
responses were determined using four concentrations (0.1-100 
µM) of the compounds (Figure 2A). For reference purposes, the 
potent hABHD16A inhibitor palmostatin B was tested at 0.01-
10 µM concentrations and in the present experiments it 
inhibited hABHD16A with an IC50 value of 99 ± 12 nM (mean 
± SD, n=2) in close agreement with our previous findings.6 For 
18 and 20, we determined the IC50 values (mean ± SD, n=2) of 
3.4 ± 0.2 µM and 5.2 ± 0.3 µM respectively. It is noteworthy 
that in contrast to palmostatin B which comprehensively 
inhibited hABHD16A in these assays, 18 and 20 could not fully 
inhibit hABHD16A activity but 12 ± 1 % and 25 ± 1% residual 
activity remained at 100 µM concentration, respectively.
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Figure 2. Biological characterization of 18 and 20 in comparison with palmostatin B. A: Dose-response curves for palmostatin B, 18 and 20 
to inhibit 1-LG hydrolysis in lysates of hABHD16A-HEK cells. Lysates were pretreated for 30 min with DMSO (control) or with the 
indicated concentrations of the inhibitors before adding the substrate (25 µM final concentration). Glycerol liberated from 1-LG hydrolysis 
was determined as previously described.6 Note that in contrast to 10 µM palmostatin B, which comprehensively blocks 1-LG hydrolysis, 
~20 % and ~30 % residual activity remains at 100 µM concentration of 18 and 20, respectively. Values are mean ±SD of duplicate wells 
from two independent experiments. B–D: Reversible nature of hABHD16A inhibition by 18 and 20. Fast 40-fold dilution of inhibitor-treated 
hABHD16A-HEK293 lysate preparation in the Reversibility Assay results in notable drop of the diterpene inhibitor potency, as compared 
to potency values obtained using the Routine Assay. In contrast, the potency for the β-lactone palmostatin B remains similar during the time-
course of this study. Data are mean ± SD from two independent experiments. E: Competitive ABPP using rat cerebellar membrane proteome 
reveals ABHD16A as the sole serine hydrolase targeted by 18 and 20. THL (10 µM), palmostatin B (10 µM) and Compound 44 (1 µM) were 
used as positive controls to identify ABHD16A and in line with our previous study,6 all three blocked TAMRA-FP labeling of a band 
migrating at ~63 kDa, corresponding to ABHD16A. Compound 18 dose-dependently inhibits TAMRA-FP labeling of ABHD16A whereas 
20 was marginally effective only at the higher concentration. Note that in contrast to THL and palmostatin B, no additional targets are evident 
for 18 or 20 among the metabolic serine hydrolases. The gel is representative of two independent ABPP runs with similar outcome. FAAH, 
fatty acid amide hydrolase; LYPLA1/2, lysophospholipase A1/A2.
To test whether 18 and 20 reversibly inhibit hABHD16A, we 
compared inhibitor potency obtained in the routine assays to 
that obtained following rapid, 40-fold dilution of the enzyme-
inhibitor complex (Figure 2B–D).8 As the compounds showed 
micromolar potency values in the routine assay, we extended 
the inhibitor concentration range up to 1 mM concentration in 
the dilution assays. A notable drop in inhibitor potency was 
evident for 18 (11.4-fold) and 20 (6.4-fold), obviously due to 
dissociation of the enzyme-inhibitor complex following the 
dilution step. In contrast, the IC50 values for the reference 
compound palmostatin B remained similar (1.8-fold change) 
between the two assay formats, indicating that within the time-
frame of these studies, the β-lactone irreversibly inhibited 
hABHD16A.
Next we probed selectivity of 18 and 20 among the serine 
hydrolase in native rat brain membrane proteome. Competitive 
ABPP was used to evaluate the hABHD16A selectivity of 18 
and 20 among the serine hydrolases in rat cerebellar membrane 
(Rcm) proteomes. We chose this proteome for these studies, as 
a recent study indicated that in the rodent brain, hABHD16A 
activity as revealed by the ABPP approach is higher in the 
cerebellum as compared to cortex and hippocampus.3 In 
competitive ABPP, binding of an inhibitor masks the enzyme's 
active site thereby inhibiting subsequent labeling with the 
active-site targeting probe. For reference purposes, the 
previously characterized hABHD16A inhibitors THL, 
palmostatin B and compound 446 were included. 
In line with previous findings,6 these experiments indicated that 
the reference inhibitors totally blocked activity probe binding to 
hABHD16A at the used concentrations (Figure 2E). As 
previously shown, palmostatin B also inhibited probe labeling 
of several additional serine hydrolases, most notably 
LYPLA1/2 in this proteome. As 18 and 20 showed reversible 
mode of inhibition in the glycerol-based hydrolase assays, these 
compounds were tested at 20 and 200 µM concentrations 
mimicking the approach that was successfully used to reveal 
serine hydrolase targets for reversible inhibitors of ABHD12.8 
Interestingly, hABHD16A was the only apparent target of 18 as 
probe labeling of this particular serine hydrolase was dose-
dependently inhibited by the two concentrations of 18. In line 
with less potent behavior in substrate-based activity assays, 20 
targeted hABHD16A less efficiently, with clearly visible effect 
only at 200 µM concentration. Interestingly, incomplete 
inhibition of ABHD16A was also evident in ABPP experiments 
using hABHD16A-HEK lysates (Figure S1), raising the 
possibility that the observed incomplete inhibitory activity 
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could derive from an allosteric rather than active site 
mechanism of binding for these abietanes.
In summary, herein we have identified 12-thiazole abietanes as 
a new class of reversible inhibitors of hABHD16A in vitro and 
detailed key structure-activity relationships for enzyme 
inhibition. The good selectivity of 18 for hABHD16A among 
other serine hydrolyses warrants further investigations into this 
class of compounds in search for more potent and equally 
selective derivatives that will surely greatly contribute towards 
translating the observed in vitro effects to an in vivo context, 
thereby establishing the significance of inhibiting this enzyme 
in neuroinflammation and inflammatory-mediated pain. 
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